| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Aktis Oncology, Inc.
13D
AKTSQ · 00973N102
|
19.3% |
1/20/2026
Event 1/12/2026
|
||||
| MPM Bioventures 2018, L.P. | 7.4% | |||||
| MPM Bioventures 2018 (B), L.P. | 0.4% | |||||
| MPM BioVentures 2018 GP LLC | 7.8% | |||||
| MPM Asset Management Investors BV2018 LLC | 0.1% | |||||
| MPM BioVentures 2018 LLC | 7.9% | |||||
| MPM Oncology Innovations Fund LP | 1.6% | |||||
| MPM Oncology Innovations Fund GP LLC | 1.6% | |||||
| Oncology Impact Private Investment Fund 2, L.P. | 9.1% | |||||
| MPM Oncology Investments 2 LLC | 9.1% | |||||
| MPM Asset Management LLC | 0.6% | |||||
| Ansbert Gadicke | 19.3% | |||||
| Luke Evnin | 9.5% | |||||
| Todd Foley | 8.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.